Papers

Peer-reviewed
Apr, 2009

Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor beta Signaling

JOURNAL OF THE NATIONAL CANCER INSTITUTE
  • Akiyoshi Komuro
  • Masakazu Yashiro
  • Caname Iwata
  • Yasuyuki Morishita
  • Erik Johansson
  • Yoshiko Matsumoto
  • Akira Watanabe
  • Hiroyuki Aburatani
  • Hiroyuki Miyoshi
  • Kunihiko Kiyono
  • Yo-taro Shirai
  • Hiroshi I. Suzuki
  • Kosei Hirakawa
  • Mitsunobu R. Kano
  • Kohei Miyazono
  • Display all

Volume
101
Number
8
First page
592
Last page
604
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1093/jnci/djp058
Publisher
OXFORD UNIV PRESS INC

Diffuse-type gastric carcinoma is a cancer with poor prognosis that has high levels of transforming growth factor beta (TGF-beta) expression and thick stromal fibrosis. However, the association of TGF-beta signaling with diffuse-type gastric carcinoma has not been investigated in detail.
We used a lentiviral infection system to express a dominant-negative TGF-beta type II receptor (dnT beta RII) or green fluorescent protein (GFP) as a control in the diffuse-type gastric carcinoma cell lines, OCUM-2MLN and OCUM-12. These infected cells and the corresponding parental control cells were subcutaneously or orthotopically injected into nude mice. Angiogenesis was inhibited by infecting cells with a lentivirus carrying the gene for angiogenic inhibitor thrombospondin-1 or by injecting mice intraperitoneally with the small-molecule angiogenic inhibitor sorafenib or with anti-vascular endothelial growth factor (VEGF) neutralizing antibody (six or eight mice per group). Expression of phospho-Smad2 and thrombospondin-1 was investigated immunologically in human gastric carcinoma tissues from 102 patients. All statistical tests were two-sided.
Expression of dnT beta RII into OCUM-2MLN cells did not affect their proliferation in vitro, but it accelerated the growth of subcutaneously or orthotopically transplanted tumors in vivo (eg, for mean volume of subcutaneous tumors on day 10 relative to that on day 0: dnT beta RII tumors = 3.49 and GFP tumors = 2.46, difference = 1.02, 95% confidence interval [CI] = 0.21 to 1.84; P = .003). The tumors expressing dnT beta RII had higher levels of angiogenesis than those expressing GFP because of decreased thrombospondin-1 production. Similar results were obtained with OCUM-12 cells. Expression of thrombospondin-1 in the dnT beta RII tumor or treatment with sorafenib or anti-VEGF antibody reduced tumor growth, whereas knockdown of thrombospondin-1 expression resulted in more accelerated growth of OCUM-2MLN tumors than of GFP tumors (eg, mean tumor volumes on day 14 relative to those on day 0: thrombospondin-1-knockdown tumors = 4.91 and GFP tumors = 3.79, difference = 1.12, 95% CI = 0.80 to 1.44; P < .001). Positive association between phosphorylated Smad2 and thrombospondin-1 immunostaining was observed in human gastric carcinoma tissues.
Disruption of TGF-beta signaling in diffuse-type gastric carcinoma models appeared to accelerate tumor growth, apparently through increased tumor angiogenesis that was induced by decreased expression of thrombospondin-1.

Link information
DOI
https://doi.org/10.1093/jnci/djp058
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/19351925
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000265272800011&DestApp=WOS_CPL
URL
http://www.scopus.com/inward/record.url?eid=2-s2.0-64749097226&partnerID=MN8TOARS
URL
http://orcid.org/0000-0003-1593-1855
ID information
  • DOI : 10.1093/jnci/djp058
  • ISSN : 0027-8874
  • eISSN : 1460-2105
  • ORCID - Put Code : 38046640
  • Pubmed ID : 19351925
  • SCOPUS ID : 64749097226
  • Web of Science ID : WOS:000265272800011

Export
BibTeX RIS